The number and frequency of intravesical instillations for non-muscle-invasive bladder cancer (NMIBC) impairs quality of life and needs to be reported in clinical trials.
In recent years the management of non-muscle-invasive bladder cancer has undergone radical changes. Intravesical Bacillus Calmette-Guérin (BCG) has long been established as the therapeutic standard ...
However, more than 50% of patients who receive initial treatment with BCG will experience disease recurrence and progression within one year, with many developing BCG-unresponsive disease. 2 Current ...
What Is BCG Treatment for Bladder Cancer? Bacillus Calmette-Guérin (BCG) is the main immunotherapy used to treat early-stage bladder cancer. Immunotherapy uses your immune system to fight cancer. BCG ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window "Medical ...
Long-term results of a phase 2 study of neoadjuvant chemotherapy combined with tislelizumab followed by radiotherapy for bladder-preserving treatment in selected high-risk/locally advanced muscle ...
rBCG offers an alternative to TICE® BCG amid U.S. shortages, impacting bladder cancer treatment availability. FDA's Expanded Access Program allows investigational rBCG use when no satisfactory ...
Credit: ImmunityBio. Nogapendekin alfa inbackicept-pmin is an interleukin-15 receptor agonist. The Food and Drug Administration (FDA) has approved Anktiva ® (nogapendekin alfa inbakicept-pmln) with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback